Cipla gains on receiving final approval for generic Pulmicort Respules

17 Nov 2017 Evaluate

Cipla is currently trading at Rs. 604.00, up by 11.00 points or 1.85% from its previous closing of Rs. 593.00 on the BSE.

The scrip opened at Rs. 605.00 and has touched a high and low of Rs. 606.00 and Rs. 601.55 respectively. So far 6,451 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 663.00 on 07-Nov-2017 and a 52 week low of Rs. 479.00 on 26-May-2017.

Last one week high and low of the scrip stood at Rs. 612.95 and Rs. 589.85 respectively. The current market cap of the company is Rs. 48,406.00 crore.

The promoters holding in the company stood at 37.26%, while Institutions and Non-Institutions held 37.49% and 25.25% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA) to market a generic version of Astrazeneca’s Pulmicort Respules.

Cipla’s Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. The product is available for shipping immediately. Pulmicort Respules and generic equivalents had US sales of approximately $825 million for the 12- month period ending September 2017, as reported by IMS Health.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally. 

Cipla Share Price

1497.45 -23.10 (-1.52%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×